Skip to content

Endoscopic Ultrasound (EUS) Fine Needle Biopsy (FNB) Submucosal Nodule

Endoscopic Ultrasound Fine Needle Biopsy of Submucosal Lesions of the GI Tract; Finding the Right Needle - A Randomized Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03011229
Enrollment
0
Registered
2017-01-05
Start date
2017-09-05
Completion date
2019-09-30
Last updated
2020-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GI Lesions

Brief summary

The purpose of this study is to compare the diagnostic accuracy of a novel endoscopic ultrasound (EUS) biopsy needle to the current standard EUS needle. The investigators hypothesize that with the SharkcoreTM needle a diagnostic yield of 90% is possible for subepithelial lesions (SEL) within the Gastrointestinal (GI) tract versus 60% yield with the current needle.

Interventions

DEVICEPro Core Needle

Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.

DEVICEmedtronic Sharkcore Needle

Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients age 18 or older referred for EUS found to have a hypoechoic lesion \> 8 mm within the GI lumen arising from the muscularis propria, as determined by EUS. * Women that have a negative pregnant test

Exclusion criteria

* Patients under the age of 18. * Uncorrectable coagulopathy (INR\>1.5) * Uncorrectable thrombocytopenia (platelet count \<50,000) * Patient who is unable to comply with study requirements * Pregnant women * Female patients who are not tested per our current unit protocol * Refusal to consent or unable to provide informed consent

Design outcomes

Primary

MeasureTime frame
diagnostic accuracy of biopsy needleend of biopsy, approximately 10 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026